Drug developers must understand the complex bioanalytical assays for cell- and gene-therapy drug development programs and ensure that partners have the specialized expertise needed for complex therapeutic classes.
Jessica St. Charles
Advertisement
Jessica St. Charles is director, laboratory sciences at Charles River Laboratories.
Articles by Jessica St. Charles
Advertisement
Latest Updated Articles
Emerging Therapies Test Existing Bioanalytical MethodsApril 15th 2019
Advertisement
Advertisement
Trending on BioPharm International
1
BioPharm Brief: Gene Therapy Progress, FDA Approval, and $103M Funding
2
Opus Genetics’ OPGx-LCA5 Gene Therapy Shows Sustained Vision Gains Ahead of Phase 3
3
Estuary Biotherapeutics Launches With $103 Million for ADPKD Gene Therapy
4
FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
5